Recon: AZ reportedly approached Gilead on merger; Aimmune touts 2-year data for peanut allergy drug

• Coronavirus drugmakers' latest tactics: Science by press release (Politico)
• The $7,000 Covid test: Why states are stepping in to shield consumers (Politico)
• Despite Big Promises, US Has Delivered Limited Aid in Global Virus Response (NYTimes)
• Scientists Are Questioning Past Research By The Founder of Surgisphere (BuzzFeed) (STAT)
• Sarepta’s gene therapy for limb-girdle disease shows improved muscle function after one year (STAT) (BioPharmaDive) (Endpoints)
• Aimmune says peanut allergy drug shows benefit after two years (Reuters)
• Biopharma IPO boom yields buoyant biotech public debuts (Endpoints)
• Will the ‘patent dance’ cause Amgen to temporarily pull a biosimilar off the market? (STAT)
• People are paying as much as $10,000 for an unlicensed remdesivir variant for their cats, in a thriving black market linked to Facebook groups (Business Insider)
• The US government's supply of the only proven Covid-19 drug runs out at the end of the month (CNN)

• Astrazeneca ‘drops interest’ in Gilead Sciences (The Times) (Bloomberg) (Endpoints)
• Oxford Biomedica eyes UK supply boost of AstraZeneca's COVID-19 vaccine (Reuters)
• Europe wants to make its own drugs, but it needs American blood plasma (Reuters)
• UK Lab to Sidestep Drug Industry to Sell Potential Virus Vaccine (NYTimes)
• EU antitrust regulators reinforce case against Teva pay-for-delay deals (Reuters)
• Fujifilm says COVID-19 drug research may drag on into July (Reuters)
• Shanghai Junshi Biosciences in human tests for coronavirus antibody drug (Reuters)
• Peter Thiel’s Palantir Is Given Access to UK Health Data on Covid-19 Patients (Bloomberg)
• WHO Finally Endorses Masks to Prevent Coronavirus Transmission (NYTimes)
• AstraZeneca blood cancer drug shows signs of helping COVID-19 patients (Reuters)
• Two fewer Notified Bodies for European CE Mark certifications (Emergo)
• Up to 12 infected in Congo's new Ebola outbreak: WHO (Reuters)

• New Coronavirus Hot Spots Emerge Across South And In California, As Northeast Slows (NPR)
• Nearly 600 — And Counting — US Health Workers Have Died Of COVID-19 (KHN)
• Japan to adopt selective, rather than blanket, approach in coronavirus tests (Reuters)
• Study: Shutdowns prevented 60 milllion coronavirus cases in US (The Hill)
• Lockdowns may have averted 3 million deaths in Europe by curbing COVID-19: study (Reuters)
• New Zealand on course to eliminate coronavirus with zero active cases (Reuters)
• Bolsonaro threatens WHO exit as COVID-19 kills 'a Brazilian per minute' (Reuters)
• Brazil stops publishing its coronavirus death toll (Politico)
• Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment (Press)
• Coronavirus (COVID-19) Update: Daily Roundup June 5, 2020 (FDA)
• False Negative Tests for SARS-CoV-2 Infection — Challenges and Implications (NEJM)
• Waiting for Certainty on Covid-19 Antibody Tests — At What Cost? (NEJM)
• Results from laboratory-based tests for COVID-19 antibodies using capillary blood sample collection kits may not be reliable (MDA/2020/015) (MHRA)
• 3D printing (additive manufacturing) of medical devices or component parts during the coronavirus (COVID-19) pandemic (MHRA)

• China’s biggest-ever Nasdaq biotech IPO comes at an awkward time (STAT)
• Alnylam sets up 3rd potential RNAi approval with a showcase of positive lumasiran data (Endpoints)
• As US calls for stateside manufacturing, antibiotic maker Paratek gambles on 'onshoring' effort (Fierce)
• Add ear gene therapy company Akouos to the ever-growing list of IPOs amid Covid-19 (Endpoints)
• Nimbus picks 4 preclinical targets for the next chapter of its pioneering computational drug discovery work (Endpoints)
• NIH — and some familiar players — back a PhII Alzheimer’s gamble in another stab at the amyloid hypothesis (Endpoints)
• When times got tough, the biopharma industry hit the Zoom button and kept things moving at a multibillion-dollar clip (Endpoints)
• Blood pressure drugs linked to lower death risk; more sensitive test recommended for blood clot risk (Reuters)
• Insmed's anti-inflammatory drug wins breakthrough status; Kyowa Kirin backs new fund from 4BIO Capital (Endpoints)
• Japan Pharma Trade Group Nudges Govt to Postpone Off-Year Re-Pricing (PharmaJapan)
• AbbVie Presents Data Showing RINVOQ™ (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA (abatacept) in Rheumatoid Arthritis Patients (Press)
• New Data from the Phase 3 HELP Study Open-Label Extension Evaluate the Long-Term Safety and Efficacy of TAKHZYRO® (lanadelumab) in Reducing Hereditary Angioedema Attacks (Press)

• FDA authorizes COVID-19 saliva test by Phosphorus Diagnostics (Reuters)
• Surmodics wins CE Mark for drug-coated balloon (MassDevice)
• Boston Scientific secures CMS pass-through nod for single-use endoscopes (MedtechDive)
• Insulet's pivotal study back on track, setting up Horizon launch in early 2021 (MedtechDive)

• Attorney General Morrisey releases results on DEA opioid investigation (The Journal)
• Four Florida Men Charged for Their Roles in a $54 Million Compound Pharmacy Kickback Scheme (DOJ)
• EMED Technologies Corp. v. Repro-Med Systems, Inc. (Fed. Cir. 2020) (Patent Docs)
• 3M Says Ex-Marine Faked Bill Gates Ties In Massive N95 Scam (Law360)
• Teva Invalidates Opiant Patents In Narcan Suit (Law360)